electroCore Expands Intellectual Property Portfolio
December 26 2023 - 8:00AM
electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
medicine and wellness company, today announced that it has received
patent issue notifications from the United States Patent and
Trademark Office (USPTO). The two patents were issued on December
26, 2023, and relate to electroCore’s non-invasive vagus nerve
stimulation (nVNS) technology:
- US Patent No. 11,850,056 entitled
“Devices and Methods for Remote Therapy and Patient Monitoring”
generally relates to systems and methods for treating medical
conditions that include delivering an nVNS therapy regimen,
detecting a heart rate variability (HRV) of the patient, and
comparing the HRV with data related to parameters of the therapy
regimen.
- US Patent No. 11,854,695 entitled
“Medical Devices for Treating Medical Conditions" generally relates
to a medical device that includes a signal generator for applying
electrical impulses to the patient for a period of time (i.e., a
single dose), wherein the device is configured to deactivate upon a
first occurrence of a specific number of single doses being applied
to the patient or a specific time elapsing after the first dose is
applied.
About electroCore, Inc.electroCore, Inc. is a
commercial stage bioelectronic medicine and wellness company
dedicated to improving health through its non-invasive vagus nerve
stimulation (“nVNS”) technology platform. Our focus is the
commercialization of medical devices for the management and
treatment of certain medical conditions and consumer product
offerings utilizing nVNS to promote general wellbeing and human
performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
Forward-Looking StatementsThis press release
and other written and oral statements made by representatives of
electroCore may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such forward-looking statements include, but are not limited to,
statements about electroCore's business prospects and clinical and
product development plans; its pipeline or potential markets for
its technologies; the timing, outcome and impact of regulatory,
clinical and commercial developments; the issuance of U.S. and
international patents providing expanded IP coverage; the
possibility of future business models, the potential of nVNS
generally and gammaCore in particular and other statements that are
not historical in nature, particularly those that utilize
terminology such as "anticipates," "expects," "believes,"
"intends," other words of similar meaning, derivations of such
words and the use of future dates. Actual results could differ from
those projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to obtain
additional financing necessary to continue electroCore's business,
sales and marketing and product development plans, the
uncertainties inherent in the development of new products or
technologies, the ability to successfully commercialize gammaCore™,
competition in the industry in which electroCore operates and
general market conditions. All forward-looking statements are made
as of the date of this press release, and electroCore undertakes no
obligation to update forward-looking statements or to update the
reasons why actual results could differ from those projected in the
forward-looking statements, except as required by law. Investors
should refer to all information set forth in this document and
should also refer to the disclosure of risk factors set forth in
the reports and other documents electroCore files with the SEC,
available at www.sec.gov.Contact:ECOR Investor
Relations(973) 302-9253investors@electrocore.com
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
electroCore (NASDAQ:ECOR)
Historical Stock Chart
From Apr 2023 to Apr 2024